Susquehanna International Group, LLP Replimune Group, Inc. Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	BUY	$5.01 - $9.46 $23,046 - $43,516	4,600 Added 35.66%	17,500 $157,000
Q1 2024 May 07, 2024	SELL	$6.87 - $9.31 $50,838 - $68,894	-7,400 Reduced 36.45%	12,900 $105,000
Q4 2023 Feb 14, 2024	SELL	$6.75 - $16.18 $2.72 Million - $6.53 Million	-403,300 Reduced 95.21%	20,300 $171,000
Q3 2023 Nov 14, 2023	BUY	$15.96 - $22.18 $6.41 Million - $8.91 Million	401,900 Added 1852.07%	423,600 $7.25 Million
Q2 2023 Aug 11, 2023	BUY	$15.65 - $24.1 $339,605 - $522,970	21,700 New	21,700 $503,000
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $8,545 - $13,955	500 Added 1.2%	42,300 $1.15 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $273,000 - $370,125	17,500 Added 72.02%	41,800 $722,000
Q2 2022 Aug 15, 2022	BUY	$13.32 - $19.98 $323,676 - $485,514	24,300 New	24,300 $425,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $616M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.